

# UCLA

## UCLA Previously Published Works

### Title

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged  $\geq 65$  Years — IVY Network, 18 States, September 8–November 30, 2022

### Permalink

<https://escholarship.org/uc/item/2n94p6qx>

### Journal

MMWR Morbidity and Mortality Weekly Report, 71(5152)

### ISSN

0149-2195

### Authors

Surie, Diya  
DeCuir, Jennifer  
Zhu, Yuwei  
et al.

### Publication Date

2022-12-01

### DOI

10.15585/mmwr.mm715152e2

Peer reviewed

## Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged $\geq 65$ Years — IVY Network, 18 States, September 8–November 30, 2022

Diya Surie, MD<sup>1,\*</sup>; Jennifer DeCuir, MD, PhD<sup>1,\*</sup>; Yuwei Zhu, MD<sup>2</sup>; Manjusha Gaglani, MBBS<sup>3,4</sup>; Adit A. Ginde, MD<sup>5</sup>; David J. Douin, MD<sup>5</sup>; H. Keipp Talbot, MD<sup>2</sup>; Jonathan D. Casey, MD<sup>2</sup>; Nicholas M. Mohr, MD<sup>6</sup>; Anne Zepeski, PharmD<sup>6</sup>; Tresa McNeal, MD<sup>3,4</sup>; Shekhar Ghamande, MD<sup>3,4</sup>; Kevin W. Gibbs, MD<sup>7</sup>; D. Clark Files, MD<sup>7</sup>; David N. Hager, MD, PhD<sup>8</sup>; Harith Ali, MBBS<sup>8</sup>; Leyla Taghizadeh<sup>9</sup>; Michelle N. Gong, MD<sup>10</sup>; Amira Mohamed, MD<sup>10</sup>; Nicholas J. Johnson, MD<sup>11</sup>; Jay S. Steingrub, MD<sup>12</sup>; Ithan D. Peltan, MD<sup>13</sup>; Samuel M. Brown, MD<sup>13</sup>; Emily T. Martin, PhD<sup>14</sup>; Akram Khan, MD<sup>15</sup>; William S. Bender, MD<sup>16</sup>; Abhijit Duggal, MD<sup>17</sup>; Jennifer G. Wilson, MD<sup>18</sup>; Nida Qadir, MD<sup>19</sup>; Steven Y. Chang, MD, PhD<sup>19</sup>; Christopher Mallow, MD<sup>20</sup>; Jennie H. Kwon, DO<sup>21</sup>; Matthew C. Exline, MD<sup>22</sup>; Adam S. Lauring, MD, PhD<sup>23</sup>; Nathan I. Shapiro, MD<sup>24</sup>; Cristie Columbus, MD<sup>4,25</sup>; Natasha Halasa, MD<sup>2</sup>; James D. Chappell, MD, PhD<sup>2</sup>; Carlos G. Grijalva, MD<sup>2</sup>; Todd W. Rice, MD<sup>2</sup>; William B. Stubblefield, MD<sup>2</sup>; Adrienne Baughman<sup>2</sup>; Kelsey N. Womack, PhD<sup>2</sup>; Jillian P. Rhoads, PhD<sup>2</sup>; Kimberly W. Hart, MA<sup>2</sup>; Sydney A. Swan, MPH<sup>2</sup>; Nathaniel M. Lewis, PhD<sup>1</sup>; Meredith L. McMorrow, MD<sup>1,†</sup>; Wesley H. Self, MD<sup>2,†</sup>; IVY Network

*On December 16, 2022, this report was posted as an MMWR Early Release on the MMWR website (<https://www.cdc.gov/mmwr>).*

Monovalent COVID-19 mRNA vaccines, designed against the ancestral strain of SARS-CoV-2, successfully reduced COVID-19–related morbidity and mortality in the United States and globally (1,2). However, vaccine effectiveness (VE) against COVID-19–associated hospitalization has declined over time, likely related to a combination of factors, including waning immunity and, with the emergence of the Omicron variant and its sublineages, immune evasion (3). To address these factors, on September 1, 2022, the Advisory Committee on Immunization Practices recommended a bivalent COVID-19 mRNA booster (bivalent booster) dose, developed against the spike protein from ancestral SARS-CoV-2 and Omicron BA.4/BA.5 sublineages, for persons who had completed at least a primary COVID-19 vaccination series (with or without monovalent booster doses)  $\geq 2$  months earlier (4). Data on the effectiveness of a bivalent booster dose against COVID-19 hospitalization in the United States are lacking, including among older adults, who are at highest risk for severe COVID-19–associated illness. During September 8–November 30, 2022, the Investigating Respiratory Viruses in the Acutely Ill (IVY) Network<sup>§</sup> assessed

effectiveness of a bivalent booster dose received after  $\geq 2$  doses of monovalent mRNA vaccine against COVID-19–associated hospitalization among immunocompetent adults aged  $\geq 65$  years. When compared with unvaccinated persons, VE of a bivalent booster dose received  $\geq 7$  days before illness onset (median = 29 days) against COVID-19–associated hospitalization was 84%. Compared with persons who received  $\geq 2$  monovalent-only mRNA vaccine doses, relative VE of a bivalent booster dose was 73%. These early findings show that a bivalent booster dose provided strong protection against COVID-19–associated hospitalization in older adults and additional protection among persons with previous monovalent-only mRNA vaccination. All eligible persons, especially adults aged  $\geq 65$  years, should receive a bivalent booster dose to maximize protection against COVID-19 hospitalization this winter season. Additional strategies to prevent respiratory illness, such as masking in indoor public spaces, should also be considered, especially in areas where COVID-19 community levels are high (4,5).

During September 8–November 30, 2022, adults aged  $\geq 65$  years admitted for COVID-19–like illness<sup>¶</sup> to any of 22 hospitals in 18 states participating in the IVY Network were eligible for inclusion in this test-negative design, case-control analysis. Among patients hospitalized with COVID-19–like illness who received testing for SARS-CoV-2 by nucleic acid amplification test or antigen test, those who received a positive test result  $\leq 10$  days after illness onset and  $\leq 3$  days after hospital admission were classified as case-patients, and those who received a negative test result during the same interval were classified as control patients. Upper respiratory specimens were collected from enrolled patients and retested by reverse transcription–polymerase chain reaction for SARS-CoV-2 and influenza at a central laboratory (Vanderbilt University Medical

\*These authors contributed equally to this report.

†These senior authors contributed equally to this report.

§The IVY Network includes the following hospitals: Baystate Medical Center (Springfield, Massachusetts), Beth Israel Deaconess Medical Center (Boston, Massachusetts), Montefiore Medical Center (New York, New York), Vanderbilt University Medical Center (Nashville, Tennessee), University of Miami Medical Center (Miami, Florida), Emory University Medical Center (Atlanta, Georgia), Johns Hopkins Hospital (Baltimore, Maryland), Wake Forest University Baptist Medical Center (Winston-Salem, North Carolina), Baylor Scott & White Health – Baylor Scott & White Medical Center (Temple, Texas), University of Iowa Hospitals (Iowa City, Iowa), University of Michigan Hospital (Ann Arbor, Michigan), Hennepin County Medical Center (Minneapolis, Minnesota), Barnes-Jewish Hospital (St. Louis, Missouri), Cleveland Clinic (Cleveland, Ohio), The Ohio State University Wexner Medical Center (Columbus, Ohio), Stanford University Medical Center (Stanford, California), UCLA Medical Center (Los Angeles, California), UCHealth University of Colorado Hospital (Aurora, Colorado), Oregon Health & Sciences University Hospital (Portland, Oregon), Intermountain Medical Center (Murray, Utah), University of Washington (Seattle, Washington), and Baylor Scott & White Health – Baylor University Medical Center (Dallas, Texas).

¶ COVID-19–like illness was defined as including any one of the following: fever, cough, shortness of breath, new or worsening findings on chest imaging consistent with pneumonia, or hypoxemia defined as oxygen saturation (SpO<sub>2</sub>)  $< 92\%$  on room air or supplemental oxygen to maintain SpO<sub>2</sub>  $\geq 92\%$ . For patients on chronic oxygen therapy, hypoxemia was defined as SpO<sub>2</sub> below baseline or an escalation of supplemental oxygen to maintain a baseline SpO<sub>2</sub>.

Center). Patients who were initially enrolled as controls on the basis of negative SARS-CoV-2 test results at their local hospital, but whose test results by central laboratory testing were positive, were reclassified as case-patients in the analysis. Control patients whose influenza test results were positive were excluded from the analysis because of potential correlation between COVID-19 and influenza vaccination behaviors (6).

Demographic and clinical data were obtained through electronic medical record (EMR) review and patient (or proxy) interview. COVID-19 mRNA vaccination status was verified from EMR, state-based registries, vaccination cards, or self-report. Three COVID-19 vaccination groups were defined as: 1) unvaccinated (no COVID-19 vaccine doses received); 2) vaccinated with  $\geq 2$  monovalent-only mRNA vaccine doses with last dose  $\geq 2$  months before illness onset; and 3) vaccinated with  $\geq 2$  monovalent-only mRNA vaccine doses plus a bivalent booster dose  $\geq 2$  months after receipt of the last monovalent mRNA vaccine dose. Analyses excluded patients with immunocompromising conditions,\*\* those who received a bivalent booster dose  $< 7$  days before illness onset or  $\leq 2$  months after their last monovalent vaccine dose, those who received a non-mRNA COVID-19 vaccine, and those with other exclusions.††

Absolute VE against COVID-19–associated hospitalization was estimated by comparing the odds of bivalent booster dose receipt with no COVID-19 vaccination between case-patients and control patients. Relative VE, which is a measure of the additional protection against COVID-19 hospitalization from a bivalent booster dose compared with residual protection from previous monovalent vaccination, was estimated by comparing the odds of bivalent booster vaccination with receipt of  $\geq 2$  monovalent-only mRNA vaccine doses between case-patients and control patients. Relative VE was stratified by number of months (i.e., 2–5, 6–11, or  $\geq 12$ ) between the last monovalent vaccine dose and illness onset. Using multivariable logistic regression models, VE was estimated as  $(1 - \text{adjusted odds ratio [aOR]}) \times 100$ . Models were adjusted for U.S. Department of Health and Human Services region, admission date in 2-week intervals, continuous age, sex, race, and Hispanic or Latino (Hispanic) ethnicity. Estimates with nonoverlapping 95% CIs

\*\* Immunocompromising conditions were defined as active solid tumor or hematologic cancer (i.e., newly diagnosed cancer or cancer treatment within the previous 6 months); solid organ transplant; bone marrow or stem cell transplant; HIV infection; congenital immunodeficiency syndrome; use of an immunosuppressive medication within the previous 30 days; splenectomy; or another condition that causes moderate or severe immunosuppression.

†† Exclusions: 1) immunocompromising conditions; 2) illness onset after hospital admission; 3) enrollment  $> 7$  days after hospital admission; 4) SARS-CoV-2-positive test result  $> 3$  days after hospital admission; 5) co-infection with influenza or respiratory syncytial virus (RSV); 6) positive influenza test result in control patients; 7) receipt of non-mRNA vaccine; 8) partial vaccination (receipt of only 1 mRNA vaccine dose); 9) receipt of last monovalent vaccine dose  $< 2$  months before illness onset; 10) receipt of bivalent vaccine dose  $< 2$  months after last monovalent dose; or 11) withdrawal from study.

were considered statistically significant. Analyses were conducted using SAS (version 9.4; SAS Institute). This activity was determined to be public health surveillance by each participating site and CDC, and was conducted consistent with all applicable federal laws and CDC policy.§§

During September 8–November 30, 2022, a total of 1,168 immunocompetent adults aged  $\geq 65$  years were enrolled in the IVY Network. After exclusion of 370 patients,¶¶ 798 (68%) were included in this analysis (381 case-patients and 417 control patients) (Table 1). The median age of included patients was 76 years (IQR = 70–83 years), 118 (15%) were non-Hispanic Black or African American, 78 (10%) were Hispanic, 588 (74%) had at least two underlying conditions, and 66 (8%) had self-reported or documented SARS-CoV-2 infection before the current illness episode during the Omicron period (December 26, 2021–November 30, 2022). Among the 381 case-patients, 81 (21%) were unvaccinated, 280 (73%) had received  $\geq 2$  monovalent-only mRNA vaccine doses, and 20 (5%) had received a bivalent booster dose. Among 417 control patients, 62 (15%) were unvaccinated, 296 (71%) had received  $\geq 2$  monovalent-only mRNA vaccine doses, and 59 (14%) had received a bivalent booster dose.

The median interval between receipt of a bivalent booster dose and illness onset was 29 days (IQR = 15–45 days) (Table 2). When compared with unvaccinated patients, VE of a bivalent booster dose in preventing COVID-19–associated hospitalization was 84%. When compared with patients who had received  $\geq 2$  monovalent-only mRNA vaccine doses  $\geq 2$  months before illness onset, relative VE of a bivalent booster dose was 73%. When compared with patients whose last monovalent dose was 6–11 months and  $\geq 12$  months before illness onset, relative VE of a bivalent booster dose was 78% and 83%, respectively. Small sample size precluded estimation of the relative VE of a bivalent booster dose compared with receipt of  $\geq 2$  monovalent-only mRNA vaccine doses with last dose 2–5 months before illness onset.\*\*\*

§§ 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.

¶¶ A total of 370 patients were excluded from the analysis for the following reasons (not mutually exclusive): patient did not meet COVID-19–like illness definition (two); illness onset occurred after hospital admission (12); patient enrolled  $> 7$  days after hospital admission (21); inability to obtain an upper respiratory sample for central laboratory testing among controls (19); SARS-CoV-2 test  $> 3$  days after hospital admission (three); SARS-CoV-2 testing indeterminate (seven); case-patient received a positive influenza test result (three); control patient received a positive influenza test result (100); influenza testing indeterminate or not done (42); case-patient received a positive RSV test result (five); inability to verify vaccination status (71); received non-mRNA vaccine (66); partial vaccination (30); received last monovalent dose  $< 2$  months before illness onset (10); received bivalent COVID-19 mRNA booster dose  $< 2$  months after last monovalent dose (three); received COVID-19 vaccines outside of CDC guidelines (13); other sex (two); or withdrew (two).

\*\*\* VE estimates with 95% CIs  $> 50$  percentage points were not reported because of lack of precision.

**TABLE 1. Characteristics of immunocompetent adults aged ≥65 years, hospitalized with COVID-like illness,\* by COVID-19 case status — IVY Network, 22 hospitals,† 18 U.S. states, September 8, 2022–November 30, 2022**

Characteristic	No. (%)		
	Total (N = 798)	COVID-19 case-patients (n = 381)	Test-negative control patients (n = 417)
<b>Vaccination status</b>			
Unvaccinated	143 (18)	81 (21)	62 (15)
≥2 Monovalent-only mRNA doses	576 (72)	280 (73)	296 (71)
Bivalent booster dose <sup>§</sup>	79 (10)	20 (5)	59 (14)
<b>Female sex</b>	442 (55)	210 (55)	232 (56)
<b>Median age, yrs (IQR)</b>	76 (70–83)	78 (71–85)	75 (69–81)
<b>Age group, yrs</b>			
65–74	345 (43)	140 (37)	205 (49)
≥75	453 (57)	241 (63)	212 (51)
<b>Race and ethnicity</b>			
Black or African American, non-Hispanic	118 (15)	52 (14)	66 (16)
Hispanic or Latino, any race	78 (10)	40 (11)	38 (9)
White, non-Hispanic	551 (69)	264 (69)	287 (69)
Other race, non-Hispanic <sup>¶</sup>	18 (2)	8 (2)	10 (2)
Other**	33 (4)	17 (4)	16 (4)
<b>HHS region<sup>†</sup></b>			
1	155 (19)	91 (24)	64 (15)
2	50 (6)	29 (8)	21 (5)
3	9 (1)	4 (1)	5 (1)
4	94 (12)	40 (11)	54 (13)
5	125 (16)	66 (17)	59 (14)
6	99 (12)	42 (11)	57 (14)
7	68 (9)	27 (7)	41 (10)
8	145 (18)	58 (15)	87 (21)
9	29 (4)	14 (4)	15 (4)
10	24 (3)	10 (3)	14 (3)
<b>No. of underlying medical conditions</b>			
0	38 (5)	15 (4)	23 (6)
1	172 (22)	91 (24)	81 (19)
2	243 (30)	115 (30)	128 (31)
≥3	345 (43)	160 (42)	185 (44)
<b>Previous Omicron infection<sup>††</sup></b>	66 (8)	24 (6)	42 (10)

## Discussion

Among immunocompetent adults aged ≥65 years hospitalized within the IVY Network in 18 states, a bivalent booster dose received after ≥2 monovalent mRNA doses provided strong protection against COVID-19–associated hospitalization during a period of Omicron BA.5 or BQ.1/BQ.1.1 predominance (7). Substantial additional protection from a bivalent booster dose was observed when compared with remote monovalent-only mRNA vaccination, which suggests important incremental benefit for persons eligible to receive a bivalent vaccine booster. These early findings from a cohort of adults aged ≥65 years, 74% of whom had multiple underlying conditions, are among the first to document real-world evidence that receipt of a bivalent booster dose after completion of at least a primary COVID-19 mRNA vaccination series is protective against COVID-19

**TABLE 1. (Continued) Characteristics of immunocompetent adults aged ≥65 years, hospitalized with COVID-like illness,\* by COVID-19 case status — IVY Network, 22 hospitals,† 18 U.S. states, September 8, 2022–November 30, 2022**

**Abbreviation:** HHS = U.S. Department of Health and Human Services.

\* COVID-19–like illness was defined as including any one of the following: fever, cough, shortness of breath, new or worsening findings on chest imaging consistent with pneumonia, or hypoxemia defined as oxygen saturation (SpO<sub>2</sub>) <92% on room air or supplemental oxygen to maintain SpO<sub>2</sub> ≥92%. For patients on chronic oxygen therapy, hypoxemia was defined as SpO<sub>2</sub> below baseline or an escalation of supplemental oxygen to maintain a baseline SpO<sub>2</sub>.

† Hospitals by HHS region included *Region 1:* Baystate Medical Center (Springfield, Massachusetts) and Beth Israel Deaconess Medical Center (Boston, Massachusetts); *Region 2:* Montefiore Medical Center (New York, New York); *Region 3:* Johns Hopkins Hospital (Baltimore, Maryland); *Region 4:* Emory University Medical Center (Atlanta, Georgia), University of Miami Medical Center (Miami, Florida), Vanderbilt University Medical Center (Nashville, Tennessee), and Wake Forest University Baptist Medical Center (Winston-Salem, North Carolina); *Region 5:* Cleveland Clinic (Cleveland, Ohio), Hennepin County Medical Center (Minneapolis, Minnesota), The Ohio State University Wexner Medical Center (Columbus, Ohio), and University of Michigan Hospital (Ann Arbor, Michigan); *Region 6:* Baylor Scott & White Health – Baylor Scott & White Medical Center (Temple, Texas) and Baylor Scott & White Health – Baylor University Medical Center (Dallas, Texas); *Region 7:* Barnes-Jewish Hospital (St. Louis, Missouri) and University of Iowa Hospitals (Iowa City, Iowa); *Region 8:* Intermountain Medical Center (Murray, Utah) and UCHealth University of Colorado Hospital (Aurora, Colorado); *Region 9:* Stanford University Medical Center (Stanford, California) and UCLA Medical Center (Los Angeles, California); and *Region 10:* Oregon Health & Science University Hospital (Portland, Oregon) and University of Washington (Seattle, Washington).

§ Bivalent COVID-19 mRNA booster dose recipients received ≥2 monovalent COVID-19 mRNA doses ≥2 months before their bivalent booster dose.

¶ Other race, non-Hispanic includes Asian, Native American or Alaska Native, and Native Hawaiian or other Pacific Islander; these groups were combined because of small counts.

\*\* Self-reported race and ethnicity as other, or patients for whom information on race and ethnicity was unavailable.

†† Previous Omicron infection was defined by date of self-reported or documented previous SARS-CoV-2 infection that occurred during December 26, 2021–November 30, 2022.

hospitalization. Continued monitoring will be important to understand ongoing protection in the context of expanding Omicron sublineages and new emerging variants, as well as whether waning of bivalent vaccine-induced immunity over time is observed, similar to that seen after monovalent COVID-19 mRNA vaccine booster doses.

Recent findings from the United Kingdom and the United States have also demonstrated protection of a bivalent mRNA booster dose against COVID-19 hospitalization (8,9). The bivalent mRNA booster vaccine used in the United Kingdom contains spike protein mRNA from ancestral SARS-CoV-2 plus Omicron BA.1, in contrast to the bivalent booster vaccines used in the United States, which contain mRNA from ancestral SARS-CoV-2 and Omicron BA.4/BA.5. In the United Kingdom, among adults aged ≥50 years or those in clinical risk groups, a BA.1 bivalent booster dose was found to have a relative VE of 57% (95% CI = 48%–65%) compared with ≥2 COVID-19 vaccine doses received ≥6 months earlier (8). Similarly, a report among adults aged ≥18 years from the VISION Network in the United States using BA.4/BA.5 bivalent booster doses showed a relative VE of



**TABLE 2. Effectiveness of a bivalent COVID-19 mRNA booster dose against COVID-19–associated hospitalization among immunocompetent adults aged ≥65 years — IVY Network, 22 hospitals,\* 18 states, September 8, 2022–November 30, 2022**

Characteristic	Received BV vaccine dose, by case status, n/N (%)		Median interval <sup>†</sup> from last vaccine dose to illness onset (IQR), days	Adjusted VE, % (95% CI) <sup>§</sup>
	Case-patients	Control patients		
<b>Absolute VE (BV booster dose versus no vaccine)</b>				
Unvaccinated (Ref)	—	—	NA	—
BV booster dose <sup>¶</sup> ≥7 days before illness onset	20/101 (20)	59/121 (49)	29 (15–45)	84 (64–93)
<b>Relative VE (BV booster dose versus MV-only, by interval since last dose)</b>				
≥2 MV-only mRNA doses, last dose ≥2 mos before illness onset (Ref)	—	—	305 (168–377)	—
BV booster dose ≥7 days before illness onset	20/300 (7)	59/355 (17)	29 (15–45)	73 (52–85)
≥2 MV-only mRNA doses, last dose 2–5 mos before illness onset (Ref)	—	—	137 (111–155)	—
BV booster dose ≥7 days before illness onset	20/82 (24)	59/155 (38)	29 (15–45)	—**
≥2 MV-only mRNA doses, last dose 6–11 mos before illness onset (Ref)	—	—	304 (258–333)	—
BV booster dose ≥7 days before illness onset	20/155 (13)	59/176 (34)	29 (15–45)	78 (57–89)
≥2 MV-only mRNA doses, last dose ≥12 mos before illness onset (Ref)	—	—	528 (386–575)	—
BV booster dose ≥7 days before illness onset	20/103 (19)	59/142 (42)	29 (15–45)	83 (63–92)

**Abbreviations:** BV = bivalent; MV = monovalent; NA = not applicable; Ref = referent group; VE = vaccine effectiveness.

\* The IVY Network includes the following hospitals: Baystate Medical Center (Springfield, Massachusetts), Beth Israel Deaconess Medical Center (Boston, Massachusetts), Montefiore Medical Center (New York, New York), Vanderbilt University Medical Center (Nashville, Tennessee), University of Miami Medical Center (Miami, Florida), Emory University Medical Center (Atlanta, Georgia), Johns Hopkins Hospital (Baltimore, Maryland), Wake Forest University Baptist Medical Center (Winston-Salem, North Carolina), Baylor Scott & White Health – Baylor Scott & White Medical Center (Temple, Texas), University of Iowa Hospitals (Iowa City, Iowa), University of Michigan Hospital (Ann Arbor, Michigan), Hennepin County Medical Center (Minneapolis, Minnesota), Barnes-Jewish Hospital (St. Louis, Missouri), Cleveland Clinic (Cleveland, Ohio), The Ohio State University Wexner Medical Center (Columbus, Ohio), Stanford University Medical Center (Stanford, California), UCLA Medical Center (Los Angeles, California), UCHealth University of Colorado Hospital (Aurora, Colorado), Oregon Health & Sciences University Hospital (Portland, Oregon), Intermountain Medical Center (Murray, Utah), University of Washington (Seattle, Washington), and Baylor Scott & White Health – Baylor University Medical Center (Dallas, Texas).

<sup>†</sup> For patients who received a BV booster dose, median time since last dose refers to the number of days between receipt of the BV booster dose and illness onset. For patients who received ≥2 MV doses without a BV booster dose, median time since last dose refers to the number of days between receipt of the last MV dose and illness onset.

<sup>§</sup> VE was estimated by comparing the odds of being BV-vaccinated among case-patients to the odds of being BV-vaccinated among control patients, calculated as  $VE = 100 \times (1 - \text{odds ratio})$ . Logistic regression models were adjusted for date of hospital admission (biweekly intervals), U.S. Department of Health and Human Services (10 regions), continuous age, sex, and race and ethnicity (non-Hispanic Black or African American, Hispanic of any race, non-Hispanic White, non-Hispanic other race, or other or unknown).

<sup>¶</sup> BV COVID-19 mRNA booster dose recipients received ≥2 MV COVID-19 mRNA doses ≥2 months before their BV booster dose.

\*\* VE estimate was not reported because of insufficient sample size. 95% CI width >50 percentage points.

42% (95% CI = 19%–58%) against COVID-19–associated hospitalization compared with ≥2 monovalent COVID-19 vaccine doses received 8–10 months earlier (9). Overall, these results were similar to the relative VE findings in the current study, suggesting that bivalent booster doses provide important benefits.

The findings in this report are subject to at least five limitations. First, the sample size was not sufficient to estimate VE by the number of COVID-19 monovalent vaccine doses received before the bivalent booster dose or compared with patients whose most recent monovalent vaccine dose was received 2–5 months before illness onset. Second, because use of monovalent COVID-19 mRNA vaccines as a booster dose is no longer authorized in the United States,<sup>†††</sup> this analysis could not compare the effectiveness of a bivalent booster dose with a monovalent booster dose administered during the same period. Third, the analysis period includes both BA.5- and BQ.1/BQ.1.1–predominant periods; therefore, variant-specific

VE could not be evaluated. Fourth, previous SARS-CoV-2 infection during the Omicron period was rarely reported or documented among patients in this analysis, which prevented evaluation of the impact of previous infection on VE. Finally, selection bias and residual confounding bias cannot be excluded, including from risk behaviors or preventive treatments.

These early findings from a multistate network show that among adults aged ≥65 years, many of whom have multiple comorbid conditions and who are at highest risk of severe COVID-19, recent bivalent booster vaccination offers substantial added protection against COVID-19 hospitalization. Although prevention of COVID-19 hospitalizations is a core goal of the U.S. vaccination program, bivalent booster dose coverage in the United States remains low among adults aged ≥18 years (16%) and adults aged ≥65 years (36%) (10). Increasing bivalent booster coverage among eligible U.S. adults has the potential to prevent COVID-19 hospitalizations as COVID-19 incidence and transmission increase. All eligible persons, especially adults aged ≥65 years, should receive a bivalent booster dose to maximize protection against COVID-19 hospitalization this winter season. Additional strategies to

<sup>†††</sup> <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use> (Accessed December 9, 2022).

**Summary****What is already known about this topic?**

Immunity from monovalent COVID-19 mRNA vaccination wanes over time. A bivalent COVID-19 mRNA booster dose is recommended for all eligible persons; however, little is known about its effectiveness against COVID-19 hospitalization.

**What is added by this report?**

Among immunocompetent adults aged  $\geq 65$  years hospitalized in the multistate IVY Network, a bivalent booster dose provided 73% additional protection against COVID-19 hospitalization compared with past monovalent mRNA vaccination only.

**What are the implications for public health practice?**

To maximize protection against severe COVID-19 this winter season, all eligible persons, especially adults aged  $\geq 65$  years, should receive a bivalent booster dose and consider additional prevention strategies, including masking in indoor public spaces.

prevent respiratory illness, such as masking in indoor public spaces, should also be considered, especially in areas where COVID-19 community levels are high (4,5).

**Acknowledgments**

Katherine E. Fleming-Dutra, Ruth Link-Gelles, Tamara Pilishvili, Ryan E. Wiegand, CDC.

Corresponding author: Diya Surie, media@cdc.gov.

<sup>1</sup>National Center for Immunization and Respiratory Diseases, CDC; <sup>2</sup>Vanderbilt University Medical Center, Nashville, Tennessee; <sup>3</sup>Baylor Scott & White Health – Baylor Scott & White Medical Center, Temple, Texas; <sup>4</sup>Texas A&M University College of Medicine, Temple, Texas; <sup>5</sup>University of Colorado School of Medicine, Aurora, Colorado; <sup>6</sup>University of Iowa, Iowa City, Iowa; <sup>7</sup>Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina; <sup>8</sup>Johns Hopkins Hospital, Baltimore, Maryland; <sup>9</sup>Hennepin County Medical Center, Minneapolis, Minnesota; <sup>10</sup>Montefiore Healthcare Center, Albert Einstein College of Medicine, New York, New York; <sup>11</sup>University of Washington School of Medicine, Seattle, Washington; <sup>12</sup>Baystate Medical Center, Springfield, Massachusetts; <sup>13</sup>Intermountain Medical Center and University of Utah, Salt Lake City, Utah; <sup>14</sup>University of Michigan School of Public Health, Ann Arbor, Michigan; <sup>15</sup>Oregon Health & Science University Hospital, Portland, Oregon; <sup>16</sup>Emory University School of Medicine, Atlanta, Georgia; <sup>17</sup>Cleveland Clinic, Cleveland, Ohio; <sup>18</sup>Stanford University School of Medicine, Stanford, California; <sup>19</sup>Ronald Reagan-UCLA Medical Center, Los Angeles, California; <sup>20</sup>University of Miami, Miami, Florida; <sup>21</sup>Washington University, St. Louis, Missouri; <sup>22</sup>The Ohio State University Wexner Medical Center, Columbus, Ohio; <sup>23</sup>University of Michigan School of Medicine, Ann Arbor, Michigan; <sup>24</sup>Beth Israel Deaconess Medical Center, Boston, Massachusetts; <sup>25</sup>Baylor Scott & White Health – Baylor University Medical Center, Dallas, Texas.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Samuel M. Brown reports serving as the data and safety monitoring board (DSMB) chair for Hamilton Ventilators outside the submitted work. Jonathan D. Casey reports grants from the National Institutes of Health (NIH) and Department of Defense (DoD), outside the submitted work. Steven Y. Chang consulted for PureTech Health in 2020 and Kiniksa Pharmaceuticals and is a DSMB member for an investigator-initiated study at UCLA.

James D. Chappell reports grants from NIH and DoD during the conduct of the study. Cristie Columbus reports support from Baylor University Medical Center for meeting attendance, an advisory role to the Dallas County Public Health Committee, and other interests as the Chief of the Division of Infectious Diseases at Baylor University Medical Center and the Medical Director for Infection Prevention and Control/Healthcare epidemiology, outside the submitted work. David J. Douin reports grants received from NIH and the National Institute of General Medical Sciences, outside the submitted work. Abhijit Duggal reports grants from NIH and the National Heart, Lung, and Blood Institute (NHLBI), and participation on a Steering Committee for ALung technologies, outside the submitted work. Matthew C. Exline reports grants from NIH and Regeneron, as well as support from Abbott Labs and Medical Legal Expert Witness for sponsored talks, outside the submitted work. D. Clark Files reports personal consultant fees from Global Blood Therapeutics and is a DSMB member from Medpace, outside the submitted work. Manjusha Gaglani reports grants from CDC-Abt Associates, CDC-Westat, and Janssen, and participates as co-chair on the Infection Diseases and Immunizations Committee for the Texas Pediatric Society, outside the submitted work. Kevin W. Gibbs reports grants from NIH and DoD, and DoD funds for the Military Health System Research Symposium travel in 2022, outside the submitted work. Adit A. Ginde reports grants from NIH, DoD, AbbVie, and Faron Pharmaceuticals, outside the submitted work. Michelle N. Gong reports grants from NHLBI and the Agency for Healthcare Research and Quality (AHRQ), speaking at medicine grand rounds at New York Medical College, travel support for the American Thoracic Society (ATS) executive meeting and serving as ATS Chair Critical Care Assembly, DSMB membership fees from Regeneron, and participating on the scientific advisory panel for Endpoint, outside the submitted work. Carlos G. Grijalva reports consultancy fees from Merck; grants from Campbell Alliance/Syneos Health, NIH, the Food and Drug Administration, and AHRQ outside the submitted work. David N. Hager reports grants from NHLBI outside the submitted work. Natasha Halasa reports grants and nonfinancial support from Sanofi, and grants from Quidel outside the submitted work. Nicholas J. Johnson reports grants from NIH, DoD, University of Washington, and Medic One Foundation, outside the submitted work. Akram Khan reports grants from United Therapeutics, Johnson & Johnson, Ely Lilly, 4D Medical, Dompe Pharmaceuticals and GlaxoSmithKline, and serves on the Guidelines committee for Chest, outside the submitted work. Jennie H. Kwon reports grants from NIH outside the submitted work. Adam S. Lauring reports personal fees from Sanofi and Roche and grants from the National Institute for Allergy and Infectious Diseases, Burroughs Wellcome Fund, Flu Lab, outside the submitted work. Emily T. Martin reports grants from Merck, Flu Lab, and NIH, outside the submitted work. Tresa McNeal reports grants from participating as a webinar invited panelist and a Practice Management Committee member for Society of Hospital Medicine, outside the submitted work. Ithan D. Peltan reports grants from NIH, Janssen Pharmaceuticals, and institutional support from Asahi Kasei Pharma and Regeneron, outside the submitted work. Todd W. Rice reports grants from NIH and DoD, personal fees from

Cumberland Pharmaceuticals, Inc., Cytovale, Inc., and Sanofi, Inc., outside the submitted work. William B. Stubblefield reports grants from NIH outside the submitted work. Jennifer G. Wilson reports personal funds from the American College of Emergency Physicians and American Board of Internal Medicine outside the submitted work. No other potential conflicts of interest were disclosed.

## References

1. Steele MK, Couture A, Reed C, et al. Estimated number of COVID-19 infections, hospitalizations, and deaths prevented among vaccinated persons in the US, December 2020 to September 2021. *JAMA Netw Open* 2022;5:e2220385. PMID:35793085 <https://doi.org/10.1001/jamanetworkopen.2022.20385>
2. Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. *Lancet Infect Dis* 2022;22:1293–302. PMID:35753318 [https://doi.org/10.1016/S1473-3099\(22\)00320-6](https://doi.org/10.1016/S1473-3099(22)00320-6)
3. Surie D, Bonnell L, Adams K, et al.; IVY Network. Effectiveness of monovalent mRNA vaccines against COVID-19–associated hospitalization among immunocompetent adults during BA.1/BA.2 and BA.4/BA.5 predominant periods of SARS-CoV-2 Omicron variant in the United States—IVY Network, 18 states, December 26, 2021–August 31, 2022. *MMWR Morb Mortal Wkly Rep* 2022;71:1327–34. PMID:36264830 <https://doi.org/10.15585/mmwr.mm7142a3>
4. Rosenblum HG, Wallace M, Godfrey M, et al. Interim recommendations from the Advisory Committee on Immunization Practices for the use of bivalent booster doses of COVID-19 vaccines—United States, October 2022. *MMWR Morb Mortal Wkly Rep* 2022;71:1436–41. PMID:36355612 <https://doi.org/10.15585/mmwr.mm7145a2>
5. CDC. COVID-19. How to protect yourself and others. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. Accessed December 15, 2022. <https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html>
6. Doll MK, Pettigrew SM, Ma J, Verma A. Effects of confounding bias in coronavirus disease 2019 (COVID-19) and influenza vaccine effectiveness test-negative designs due to correlated influenza and COVID-19 vaccination behaviors. *Clin Infect Dis* 2022;75:e564–71. PMID:35325923 <https://doi.org/10.1093/cid/ciac234>
7. CDC. COVID data tracker: variant proportions. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. Accessed December 14, 2022. <https://covid.cdc.gov/covid-data-tracker/#variant-proportions>
8. UK Health Security Agency. COVID-19 vaccine surveillance report: week 48. London, United Kingdom: UK Health Security Agency; 2022. [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1121345/vaccine-surveillance-report-week-48-2022.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1121345/vaccine-surveillance-report-week-48-2022.pdf). Accessed December 10, 2022.
9. Tenforde MW, Weber ZA, Natarajan K, et al. Effectiveness of bivalent mRNA vaccines in preventing COVID-19–associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults—VISION Network, nine states, September–November 2022. *MMWR Morb Mortal Wkly Rep* 2022;71. Epub December 16, 2022. [https://www.cdc.gov/mmwr/volumes/71/wr/mm715152e1.htm?s\\_cid=mm715152e1\\_w](https://www.cdc.gov/mmwr/volumes/71/wr/mm715152e1.htm?s_cid=mm715152e1_w)
10. CDC. COVID data tracker: COVID-19 vaccinations in the United States. Atlanta, GA: US Department of Health and Human Services, CDC; 2022. Accessed December 10, 2022. [https://covid.cdc.gov/covid-data-tracker/#vaccinations\\_vacc-people-booster-percent-pop5](https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-booster-percent-pop5)